Get my own profile
Public access
View all70 articles
1 article
available
not available
Based on funding mandates
Co-authors
Nicholas P Restifo, MDCellular Immunotherapy ExplorerVerified email at marbletx.com
Steven A RosenbergNCIVerified email at nih.gov
Luca GattinoniLeibniz Institute for Immunotherapy (LIT)Verified email at lit.eu
toren finkelUniversity of PittsburghVerified email at pitt.edu
Alena GrosVall d'Hebron Institute of OncologyVerified email at vhio.net
Gautam MehtaFDA OncologyVerified email at fda.hhs.gov
Luis Sanchez-PerezTune TherapeuticsVerified email at duke.edu
Klaus OkkenhaugDivision of Immunology, Department of Pathology, University of CambridgeVerified email at cam.ac.uk
Mark E DudleyCSO, Instil BioVerified email at instilbio.com
Nicholas KlemenNational Cancer InstituteVerified email at nih.gov
Pós ZoltánAssistant Professor, Dept. Of Genetics, Cell and Immunobiology, Semmelweis UniversityVerified email at med.semmelweis-univ.hu
Eric TranEarle A. Chiles Research Institute, Providence Cancer CenterVerified email at providence.org
suman mitraPrincipal investigator, Univ. Lille, CANTHER, CNRS 9020, INSERM UMR 1277, CHU Lille,Verified email at inserm.fr
Jason A. HallAbbVieVerified email at abbvie.com
Rongman CaiNIHVerified email at nih.gov
Sean SpencerStanford UniversityVerified email at stanford.edu
Lukas FlatzUniversity of Tübingen (Medical Faculty)Verified email at med.uni-tuebingen.de
CAstraZeneca
Follow![Christopher A. Klebanoff, M.D.](https://scholar.googleusercontent.com/citations?view_op=view_photo&user=zO70sG0AAAAJ&citpid=6)
Christopher A. Klebanoff, M.D.
Associate Member, Memorial Sloan Kettering Cancer Center
Verified email at mskcc.org